|
|
 |
|
Viewing report
|
|
|
|
Innovations in Molecular Diagnostics for Infectious Diseases
Business Insights, Nov 2011, Pages: 168
This report examines the opportunities presented to the developers of molecular diagnostics by the emergence of novel/variant pathogens and ways in which new molecular testing technologies are being translated into superior diagnostic products in areas such as healthcare-associated infections; HPV infections, blood-borne viral infections and respiratory viral infections.
Features and benefits:
- Understand the nature and limitations of traditional molecular diagnostics and the improved features of molecular testing technologies in development.
- Evaluate the competitive landscape in infectious disease molecular diagnostics and identify potential licensing/collaborative partners.
- Analyze the factors stimulating increased demand for molecular testing in specific infectious disease areas to inform investment decisions.
- Gain an insight into new and untapped opportunities revealed by recent research findings in the more mature sectors of the MDx market.
- Identify key trends in the MDx market and plan future developments with the aid of market forecasts for the individual segments of the market.
Highlights:
- The latest molecular diagnostics to enter development are multiplex tests which can identify several pathogens or variants of these pathogens present in small-volume samples. Low- and medium-density bead-based microarrays are being developed and are expected to play an increasingly important role in multiplex pathogen detection and genotyping.
- It is likely that future diagnostic tests will target many more pathogens than is currently the case. Promising approaches include miniaturized microfluidic systems, in particular continuous-flow droplet-based PCR systems, and mass spectrometry-based detection methods which use direct specimen testing and virtually no reagents.
- Growth forecasts are derived for key MDx market segments for the period 2010-2015: the HPV testing market is forecast to grow with a 5-year CAGR of 20%, the hospital-associated infection (HAI) testing market is forecast to grow with a 5-year CAGR of 19%. and the virology (HIV/HCV/HBV) testing market is forecast to grow with a 5-year CAGR of 8%.
Your key questions answered:
- Which are the areas of unmet need in infectious disease testing and potential new areas of opportunity for MDx in infectious disease?
- What forces are shaping molecular diagnostic testing trends and what drivers and restraints operate in the infectious disease testing market?
- Who is developing new innovative products for the infectious disease MDx market and what paths to commercialization are they following?
- How are the different sectors of the infectious disease MDx market forecast to develop and what are the prospects for new market entrants?
- What are the estimated current market sizes and 5-year growth forecasts for the expanding sectors of the infectious disease MDx market?
|
|
|
|
